Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of ...

Praluent, a PCSK9 inhibitor, was developed by Regeneron (REGN) and Sanofi (SNY) under a global collaboration agreement. The medication is currently indicated to treat both children and adults with ...

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another ...

Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales ...